Nabriva Financial Statements From 2010 to 2025
Nabriva Therapeutics financial statements provide useful quarterly and yearly information to potential Nabriva Therapeutics AG investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Nabriva Therapeutics financial statements helps investors assess Nabriva Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Nabriva Therapeutics' valuation are summarized below:Nabriva Therapeutics AG does not presently have any fundamental ratios for analysis.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Check Nabriva Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nabriva Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Nabriva financial statements analysis is a perfect complement when working with Nabriva Therapeutics Valuation or Volatility modules.
Nabriva |
Nabriva Therapeutics AG Company Return On Equity Analysis
Nabriva Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Nabriva Therapeutics Return On Equity | -2.69 |
Most of Nabriva Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nabriva Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Nabriva Therapeutics AG has a Return On Equity of -2.6853. This is 88.8% lower than that of the Pharmaceuticals sector and 92.63% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Nabriva Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nabriva Therapeutics's current stock value. Our valuation model uses many indicators to compare Nabriva Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nabriva Therapeutics competition to find correlations between indicators driving Nabriva Therapeutics's intrinsic value. More Info.Nabriva Therapeutics AG is regarded third in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Nabriva Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |